SK283301B6 - Použitie farmaceutickej zmesi na ústne podanie - Google Patents

Použitie farmaceutickej zmesi na ústne podanie Download PDF

Info

Publication number: SK283301B6
Authority: SK; Slovakia
Prior art keywords: apomorphine; active ingredient; usp; mixture; composition
Prior art date: 1997-01-17

Application number

SK972-99A

Other languages

English (en)

Slovak (sk)

Other versions

SK97299A3 (en

Inventor

Edward Stewart Johnson

Anthony Clarke

Richard David Green

Original Assignee

R. P. Scherer Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-17

Filing date

1998-01-16

Publication date

2003-05-02

1998-01-16 Application filed by R. P. Scherer Limited filed Critical R. P. Scherer Limited

2000-11-07 Publication of SK97299A3 publication Critical patent/SK97299A3/sk

2003-05-02 Publication of SK283301B6 publication Critical patent/SK283301B6/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
239000000203 mixture Substances 0.000 claims abstract description 45
239000002552 dosage form Substances 0.000 claims abstract description 33
239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 27
239000004480 active ingredient Substances 0.000 claims abstract description 23
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 16
208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 10
201000001881 impotence Diseases 0.000 claims abstract description 9
210000000214 mouth Anatomy 0.000 claims abstract description 8
229960003604 testosterone Drugs 0.000 claims abstract description 8
238000011282 treatment Methods 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims abstract description 4
229960004046 apomorphine Drugs 0.000 claims description 45
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical group C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 33
239000002111 antiemetic agent Substances 0.000 claims description 15
230000003474 anti-emetic effect Effects 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 10
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 9
229960001253 domperidone Drugs 0.000 claims description 8
239000007787 solid Substances 0.000 claims description 7
230000008022 sublimation Effects 0.000 claims 1
238000000859 sublimation Methods 0.000 claims 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
108010010803 Gelatin Proteins 0.000 description 19
239000008273 gelatin Substances 0.000 description 19
229920000159 gelatin Polymers 0.000 description 19
235000019322 gelatine Nutrition 0.000 description 19
235000011852 gelatine desserts Nutrition 0.000 description 19
239000011159 matrix material Substances 0.000 description 18
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 17
229930195725 Mannitol Natural products 0.000 description 17
239000000594 mannitol Substances 0.000 description 17
235000010355 mannitol Nutrition 0.000 description 17
239000008896 Opium Substances 0.000 description 16
239000012153 distilled water Substances 0.000 description 16
229960001027 opium Drugs 0.000 description 16
239000000654 additive Substances 0.000 description 15
230000000996 additive effect Effects 0.000 description 15
108010011485 Aspartame Proteins 0.000 description 14
239000005557 antagonist Substances 0.000 description 14
239000000605 aspartame Substances 0.000 description 14
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 14
235000010357 aspartame Nutrition 0.000 description 14
229960003438 aspartame Drugs 0.000 description 14
CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 description 12
238000012792 lyophilization process Methods 0.000 description 12
230000000694 effects Effects 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
229940125683 antiemetic agent Drugs 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000003826 tablet Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
229940052760 dopamine agonists Drugs 0.000 description 7
230000001568 sexual effect Effects 0.000 description 7
239000000796 flavoring agent Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
229960003990 apomorphine hydrochloride Drugs 0.000 description 5
230000008901 benefit Effects 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
239000003210 dopamine receptor blocking agent Substances 0.000 description 5
235000019634 flavors Nutrition 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
244000246386 Mentha pulegium Species 0.000 description 4
235000016257 Mentha pulegium Nutrition 0.000 description 4
235000004357 Mentha x piperita Nutrition 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
229960002802 bromocriptine Drugs 0.000 description 4
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
235000001050 hortel pimenta Nutrition 0.000 description 4
239000008368 mint flavor Substances 0.000 description 4
210000003899 penis Anatomy 0.000 description 4
230000009467 reduction Effects 0.000 description 4
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
-1 cyclic sugars Chemical class 0.000 description 3
238000007710 freezing Methods 0.000 description 3
230000008014 freezing Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 3
229960003086 naltrexone Drugs 0.000 description 3
230000008693 nausea Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
229960001879 ropinirole Drugs 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000007086 side reaction Methods 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000006190 sub-lingual tablet Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
235000005979 Citrus limon Nutrition 0.000 description 2
244000131522 Citrus pyriformis Species 0.000 description 2
240000000560 Citrus x paradisi Species 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
208000008454 Hyperhidrosis Diseases 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
235000011034 Rubus glaucus Nutrition 0.000 description 2
244000235659 Rubus idaeus Species 0.000 description 2
235000009122 Rubus idaeus Nutrition 0.000 description 2
206010039897 Sedation Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
229930013930 alkaloid Natural products 0.000 description 2
150000003797 alkaloid derivatives Chemical class 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
239000007958 cherry flavor Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
235000009508 confectionery Nutrition 0.000 description 2
230000000095 emetic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000005562 fading Methods 0.000 description 2
239000011888 foil Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
229960003587 lisuride Drugs 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
229960004127 naloxone Drugs 0.000 description 2
JCSREICEMHWFAY-HUUCEWRRSA-N naxagolide Chemical compound C1=C(O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 JCSREICEMHWFAY-HUUCEWRRSA-N 0.000 description 2
229950005651 naxagolide Drugs 0.000 description 2
239000003002 pH adjusting agent Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229960004310 piribedil Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000004044 response Effects 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
230000036280 sedation Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000035900 sweating Effects 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000006068 taste-masking agent Substances 0.000 description 2
RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 description 1
UZHSEJADLWPNLE-OGLQFSJHSA-N (4R,4aS,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O1C2C(=O)CC[C@@]3(O)[C@]4([H])N(CC=C)CC[C@]23C2=C1C(O)=CC=C2C4 UZHSEJADLWPNLE-OGLQFSJHSA-N 0.000 description 1
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
BTJMOXDWIPVCRO-UHFFFAOYSA-N 2,3,4-trimethoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C(OC)=C1OC BTJMOXDWIPVCRO-UHFFFAOYSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
CVQFAMQDTWVJSV-LQGIQHHOSA-N 3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 CVQFAMQDTWVJSV-LQGIQHHOSA-N 0.000 description 1
VMWNQDUVQKEIOC-UHFFFAOYSA-N 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol Chemical compound C1CN(C)C2CC3=CC=C(O)C(O)=C3C3=C2C1=CC=C3 VMWNQDUVQKEIOC-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000303040 Glycyrrhiza glabra Species 0.000 description 1
235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
QYZRTBKYBJRGJB-PCMHIUKPSA-N Granisetron hydrochloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-PCMHIUKPSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
229930182844 L-isoleucine Natural products 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
206010034319 Penile swelling Diseases 0.000 description 1
108010064851 Plant Proteins Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
235000005805 Prunus cerasus Nutrition 0.000 description 1
244000207449 Prunus puddum Species 0.000 description 1
235000009226 Prunus puddum Nutrition 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
244000290333 Vanilla fragrans Species 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
241000219094 Vitaceae Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002156 adsorbate Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000021120 animal protein Nutrition 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
229960004596 cabergoline Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000007368 endocrine function Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000004088 foaming agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
229960003727 granisetron Drugs 0.000 description 1
235000021021 grapes Nutrition 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
235000011477 liquorice Nutrition 0.000 description 1
229960000418 lisuride maleate Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960004650 metergoline Drugs 0.000 description 1
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
229960001566 methyltestosterone Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
229960001511 pergolide mesylate Drugs 0.000 description 1
UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
210000002640 perineum Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
235000021118 plant-derived protein Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
230000001007 puffing effect Effects 0.000 description 1
229960000924 quinagolide Drugs 0.000 description 1
125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000011514 reflex Effects 0.000 description 1
239000012744 reinforcing agent Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960004558 terguride Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Gynecology & Obstetrics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK972-99A 1997-01-17 1998-01-16 Použitie farmaceutickej zmesi na ústne podanie SK283301B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9700878.3A GB9700878D0 (en)	1997-01-17	1997-01-17	Dosage forms and method for ameliorating male erectile dysfunction
PCT/GB1998/000143 WO1998031368A1 (en)	1997-01-17	1998-01-16	Dosage forms and method for ameliorating male erectile dysfunction

Publications (2)

Publication Number	Publication Date
SK97299A3 SK97299A3 (en)	2000-11-07
SK283301B6 true SK283301B6 (sk)	2003-05-02

Family

ID=10806104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK972-99A SK283301B6 (sk)	1997-01-17	1998-01-16	Použitie farmaceutickej zmesi na ústne podanie

Country Status (27)

Country	Link
US (2)	US6342246B2 (de)
EP (1)	EP0954314B1 (de)
JP (1)	JP2000513736A (de)
KR (1)	KR100416768B1 (de)
CN (1)	CN1243440A (de)
AT (1)	ATE211385T1 (de)
AU (1)	AU717337B2 (de)
BG (1)	BG103570A (de)
BR (1)	BR9808888A (de)
CA (1)	CA2276758A1 (de)
DE (1)	DE69803360T2 (de)
DK (1)	DK0954314T3 (de)
EE (1)	EE03805B1 (de)
ES (1)	ES2167061T3 (de)
GB (1)	GB9700878D0 (de)
HU (1)	HUP0001089A3 (de)
IL (1)	IL130714A0 (de)
NO (1)	NO993520L (de)
NZ (1)	NZ336436A (de)
PL (1)	PL334656A1 (de)
PT (1)	PT954314E (de)
RU (1)	RU2204413C2 (de)
SK (1)	SK283301B6 (de)
TR (1)	TR199901669T2 (de)
UA (1)	UA62954C2 (de)
WO (1)	WO1998031368A1 (de)
YU (1)	YU33099A (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6121276A (en) *	1994-04-22	2000-09-19	Pentech Pharmaceuticals, Inc.	Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
GB9813278D0 (en) *	1998-06-20	1998-08-19	Medical Res Council	Male contraceptive
JP2000178204A (ja) *	1998-10-05	2000-06-27	Eisai Co Ltd	ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
CA2251255A1 (en) *	1998-10-20	2000-04-20	Mcgill University	The use of dopaminergic agents in the management of sexual dysfunction
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
KR20030036157A (ko)	2000-04-07	2003-05-09	탭 파마슈티칼 프로덕츠 인코포레이티드	아포모르핀 유도체 및 이의 사용 방법
SE0002934D0 (sv)	2000-08-17	2000-08-17	Axon Biochemicals Bv	New aporphine esters and in their use in therapy
SE0102036D0 (sv) *	2001-06-08	2001-06-08	Axon Biochemicals Bv	Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
ES2341090T3 (es) *	2000-08-30	2010-06-15	Unimed Pharmaceuticals, Llc	Procedimiento para tratar la disfuncion erectil y aumentar la libido en hombres.
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20020103105A1 (en) *	2000-11-22	2002-08-01	Brioni Jorge D.	Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
US6960589B2 (en)	2001-03-09	2005-11-01	Abbott Laboratories	Benzimidazoles that are useful in treating sexual dysfunction
US20020169166A1 (en) *	2001-03-09	2002-11-14	Cowart Marlon D.	Benzimidazoles that are useful in treating sexual dysfunction
US7022728B2 (en)	2001-03-09	2006-04-04	Abbott Laboratories	Benzimidazoles that are useful in treating male sexual dysfunction
US20030008878A1 (en) *	2001-03-09	2003-01-09	Cowart Marlon D.	Benzimidazoles that are useful in treating sexual dysfunction
FR2834894B1 (fr) *	2002-01-21	2004-02-27	Servier Lab	Composition pharmaceutique orodispersible de piribedil
FR2834897B1 (fr) *	2002-01-23	2004-02-27	Servier Lab	Composition pharmaceutique orodispersible de testosterone
AU2003215461A1 (en) *	2002-03-26	2003-10-08	Bernard Charles Sherman	Stable tablets comprising pergolide mesylate
US20040220190A1 (en) *	2002-07-29	2004-11-04	Cincotta Anthony H.	Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en)	2002-08-09	2014-09-02	Veroscience, Llc	Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040115287A1 (en) *	2002-12-17	2004-06-17	Lipocine, Inc.	Hydrophobic active agent compositions and methods
US20040156894A1 (en) *	2003-02-07	2004-08-12	Grother Leon Paul	Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
SI1610791T1 (sl)	2003-03-31	2011-05-31	Titan Pharmaceuticals Inc	Implantibilna polimerna naprava za zadrĹľano sproĹˇÄŤanje dopaminskega agonista
US20050137265A1 (en) *	2003-03-31	2005-06-23	Haley Eugene T.	Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040202717A1 (en) *	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
WO2005021056A1 (en) *	2003-08-21	2005-03-10	Cns, Inc.	Effervescent delivery system
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
RU2283650C1 (ru) *	2005-02-24	2006-09-20	Закрытое Акционерное Общество "Канонфарма Продакшн"	Твердая лекарственная форма для улучшения мужской эректильной функции
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
US8241664B2 (en)	2005-04-15	2012-08-14	Clarus Therapeutics, Inc	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en)	2010-04-12	2013-07-23	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
RS52671B (sr)	2005-10-12	2013-06-28	Unimed Pharmaceuticals Llc	Poboljšani gel testosterona i postupak korišćenja
EP2043613A1 (de) *	2006-07-14	2009-04-08	Fmc Corporation	Feste form
US20080311162A1 (en) *	2007-05-16	2008-12-18	Olivia Darmuzey	Solid form
US8741918B2 (en)	2007-06-21	2014-06-03	Veroscience Llc	Parenteral formulations of dopamine agonists
US20100035886A1 (en)	2007-06-21	2010-02-11	Veroscience, Llc	Parenteral formulations of dopamine agonists
US8861813B2 (en) *	2008-03-13	2014-10-14	Mallinckrodt Llc	Multi-function, foot-activated controller for imaging system
US20100168119A1 (en) *	2008-11-05	2010-07-01	Pharmorx, Inc.	Compositions and methods for minimizing or reducing agonist-induced desensitization
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US9352025B2 (en)	2009-06-05	2016-05-31	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2011026080A1 (en)	2009-08-31	2011-03-03	Wilmington Pharmaceuticals, Llc	Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain
US12186426B2 (en)	2009-10-30	2025-01-07	Ix Biopharma Ltd.	Solid dosage form
WO2011053251A1 (en)	2009-10-30	2011-05-05	Ix Biopharma Pte Ltd	Fast dissolving solid dosage form
CN101797260B (zh) *	2009-12-23	2011-09-21	济南圣泉唐和唐生物科技有限公司	L-阿拉伯糖在制备用于治疗阴茎勃起障碍药物中的用途
BR112013009255B1 (pt) *	2010-10-08	2021-02-23	R.P. Scherer Technologies, Llc	composição sólida de vacina oral de dissolução rápida
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
EP2854764B1 (de) *	2012-06-05	2018-12-12	Neuroderm Ltd	Zusammensetzungen mit apomorphin und organischen säuren und verwendungen davon
CA2899455C (en)	2013-01-30	2021-06-08	Pharmorx Therapeutics, Inc.	Treatments for depression and other diseases with a low dose agent
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en)	2016-11-28	2018-05-31	Nachiappan Chidambaram	Oral testosterone undecanoate therapy
EP3824296B1 (de)	2018-07-20	2026-04-01	Lipocine Inc.	Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen
US11564933B2 (en)	2019-04-12	2023-01-31	Tolmar, Inc.	Methods of treating testosterone deficiency

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3928566A (en) *	1970-08-14	1975-12-23	Du Pont	Lyophilized biological products
US4098802A (en) *	1975-02-18	1978-07-04	Akzona Incorporated	Oral pharmaceutical preparation having androgenic activity
GB1548022A (en) *	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
US4877774A (en) *	1987-09-09	1989-10-31	The United States Of America As Represented By The Department Of Health And Human Services	Administration of steroid hormones
US5135752A (en) *	1988-10-14	1992-08-04	Zetachron, Inc.	Buccal dosage form
US5125752A (en) *	1990-11-06	1992-06-30	Ndsu-Research Foundation	Mixer
HUT75616A (en) *	1992-03-17	1997-05-28	Pfizer	Method for prooucing porous delivery devices
RU2026643C1 (ru) *	1992-12-25	1995-01-20	Зыбин Дмитрий Владимирович	Способ лечения больных с нарушением мужской половой функции методом трансплантации
HUT74514A (en) *	1994-01-27	1997-01-28	Janssen Pharmaceutica Nv	Rapidly dissolving oral dosage form
US5576014A (en) *	1994-01-31	1996-11-19	Yamanouchi Pharmaceutical Co., Ltd	Intrabuccally dissolving compressed moldings and production process thereof
ATE312609T1 (de) *	1994-04-22	2005-12-15	Pentech Pharmaceuticals Inc	Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5624677A (en) *	1995-06-13	1997-04-29	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) *	1995-08-18	1995-10-25	Scherer Ltd R P	Pharmaceutical compositions

1997
- 1997-01-17 GB GBGB9700878.3A patent/GB9700878D0/en active Pending
1998
- 1998-01-16 DK DK98900902T patent/DK0954314T3/da active
- 1998-01-16 PT PT98900902T patent/PT954314E/pt unknown
- 1998-01-16 SK SK972-99A patent/SK283301B6/sk unknown
- 1998-01-16 YU YU33099A patent/YU33099A/sh unknown
- 1998-01-16 RU RU99117926/14A patent/RU2204413C2/ru not_active IP Right Cessation
- 1998-01-16 EE EEP199900288A patent/EE03805B1/xx not_active IP Right Cessation
- 1998-01-16 UA UA99084671A patent/UA62954C2/uk unknown
- 1998-01-16 IL IL13071498A patent/IL130714A0/xx unknown
- 1998-01-16 HU HU0001089A patent/HUP0001089A3/hu unknown
- 1998-01-16 PL PL98334656A patent/PL334656A1/xx unknown
- 1998-01-16 JP JP10533951A patent/JP2000513736A/ja active Pending
- 1998-01-16 EP EP98900902A patent/EP0954314B1/de not_active Expired - Lifetime
- 1998-01-16 NZ NZ336436A patent/NZ336436A/xx unknown
- 1998-01-16 WO PCT/GB1998/000143 patent/WO1998031368A1/en not_active Ceased
- 1998-01-16 CN CN98801849A patent/CN1243440A/zh active Pending
- 1998-01-16 CA CA002276758A patent/CA2276758A1/en not_active Abandoned
- 1998-01-16 ES ES98900902T patent/ES2167061T3/es not_active Expired - Lifetime
- 1998-01-16 AU AU56710/98A patent/AU717337B2/en not_active Ceased
- 1998-01-16 BR BR9808888-2A patent/BR9808888A/pt not_active Application Discontinuation
- 1998-01-16 AT AT98900902T patent/ATE211385T1/de not_active IP Right Cessation
- 1998-01-16 KR KR10-1999-7006492A patent/KR100416768B1/ko not_active Expired - Fee Related
- 1998-01-16 DE DE69803360T patent/DE69803360T2/de not_active Expired - Fee Related
- 1998-01-16 TR TR1999/01669T patent/TR199901669T2/xx unknown
1999
- 1999-07-12 BG BG103570A patent/BG103570A/bg unknown
- 1999-07-12 US US09/352,515 patent/US6342246B2/en not_active Expired - Fee Related
- 1999-07-16 NO NO993520A patent/NO993520L/no unknown
2001
- 2001-12-24 US US10/026,492 patent/US20020156056A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO993520D0 (no)	1999-07-16
EE03805B1 (et)	2002-08-15
TR199901669T2 (xx)	2000-07-21
KR20000070264A (ko)	2000-11-25
CN1243440A (zh)	2000-02-02
CA2276758A1 (en)	1998-07-23
WO1998031368A1 (en)	1998-07-23
IL130714A0 (en)	2000-06-01
SK97299A3 (en)	2000-11-07
GB9700878D0 (en)	1997-03-05
UA62954C2 (en)	2004-01-15
RU2204413C2 (ru)	2003-05-20
BG103570A (bg)	2000-04-28
BR9808888A (pt)	2000-10-03
DK0954314T3 (da)	2002-02-18
DE69803360D1 (de)	2002-02-28
US20010018069A1 (en)	2001-08-30
AU5671098A (en)	1998-08-07
KR100416768B1 (ko)	2004-01-31
ES2167061T3 (es)	2002-05-01
PT954314E (pt)	2002-06-28
US6342246B2 (en)	2002-01-29
US20020156056A1 (en)	2002-10-24
EP0954314B1 (de)	2002-01-02
JP2000513736A (ja)	2000-10-17
PL334656A1 (en)	2000-03-13
AU717337B2 (en)	2000-03-23
HUP0001089A3 (en)	2001-03-28
HUP0001089A2 (hu)	2000-11-28
EP0954314A1 (de)	1999-11-10
YU33099A (sh)	2002-06-19
ATE211385T1 (de)	2002-01-15
EE9900288A (et)	2000-02-15
NO993520L (no)	1999-09-16
DE69803360T2 (de)	2002-10-10
NZ336436A (en)	2000-07-28

Publication	Publication Date	Title
SK97299A3 (en)	2000-11-07	The use of a pharmaceutical composition for oral administration
US6316027B1 (en)	2001-11-13	Fast-dissolving dosage forms for dopamine agonists
US6680071B1 (en)	2004-01-20	Opioid agonist in a fast dispersing dosage form
CA2336095A1 (en)	1999-12-29	Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
JP2003521462A (ja)	2003-07-15	男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用
JPH10506409A (ja)	1998-06-23	モノアミンオキシダーゼｂインヒビターからなる医薬組成物
JP2003507420A (ja)	2003-02-25	作用物質の組成物、クロニジンを含む前記組成物
WO2000051539A1 (en)	2000-09-08	Opioid agonist in a fast dispersing dosage form
CZ247299A3 (cs)	2000-01-12	Použití farmaceutické směsi pro ústní podání
CN118141810A (zh)	2024-06-07	用于治疗性治疗的包含加波沙朵的药物制剂
MXPA99006585A (en)	2000-06-01	Dosage forms and method for ameliorating male erectile dysfunction
MXPA01006105A (es)	2002-05-09	Uso de apomorfina en la elaboracion de un medicamento para el tratamiento de la disfuncion erectil organica en los hombres